TY - JOUR
T1 - Hemodynamic effects of fluoxetine in pulmonary arterial hypertension
T2 - an open label pilot study
AU - Sodimu, Adetoun
AU - Bartolome, Sonja
AU - Igenoza, Oluwatosin P.
AU - Chin, Kelly M.
N1 - Publisher Copyright:
© The Author(s) 2020.
PY - 2020
Y1 - 2020
N2 - In order to evaluate the therapeutic potential of fluoxetine in pulmonary arterial hypertension, 13 patients with pulmonary arterial hypertension underwent catheterization before and after 12 (N = 5) or 24 (N = 8) weeks fluoxetine therapy. No change was seen in the primary endpoint of pulmonary vascular resistance, other hemodynamic values, or any secondary endpoints.
AB - In order to evaluate the therapeutic potential of fluoxetine in pulmonary arterial hypertension, 13 patients with pulmonary arterial hypertension underwent catheterization before and after 12 (N = 5) or 24 (N = 8) weeks fluoxetine therapy. No change was seen in the primary endpoint of pulmonary vascular resistance, other hemodynamic values, or any secondary endpoints.
KW - pulmonary hypertension
KW - right heart catheterization treatment
UR - http://www.scopus.com/inward/record.url?scp=85096623857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096623857&partnerID=8YFLogxK
U2 - 10.1177/2045894020971954
DO - 10.1177/2045894020971954
M3 - Article
C2 - 33282204
AN - SCOPUS:85096623857
SN - 2045-8932
VL - 10
JO - Pulmonary Circulation
JF - Pulmonary Circulation
IS - 4
ER -